person · Reporting owner
Waldman Reid Alexander
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | July 27, 2026 | July 29, 2026 |
| Veradermics, IncMANE · Entity 1907 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.18 · Expires 2036-07-27 | Direct | 25,000 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2036-07-27 | Direct | 16,700 |
Reported balance
After 2026-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-27 · Grant · Acquired 16,700 · Balance 16,700 F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Veradermics, Inc
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 170,824 |
Ending reported balance
After 2026-08-17 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 3,452 · Balance 238,324 Row 2 · 2026-08-17 · Sale · Disposed 11,527 · Balance 226,797 F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.07 to $107.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-08-17 · Sale · Disposed 25,234 · Balance 201,563 F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $108.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-08-17 · Sale · Disposed 27,490 · Balance 174,073 F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-08-17 · Sale · Disposed 3,000 · Balance 171,073 F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.02 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2026-08-17 · Sale · Disposed 249 · Balance 170,824 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.19 · Expires 2026-12-12 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-17 · Exercise / conversion · Disposed 3,452 · Balance 0 F5: This option is fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.07 to $107.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $108.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.02 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: This option is fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,452 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · derivative · entry 7 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,452 shares Expires 2026-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 249 | $111.28 | $27,708.72 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 6 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,824 Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 3,000 | $109.38 | $328,140.00 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 5 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,073 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.02 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 27,490 | $108.45 | $2,981,290.50 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 4 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,073 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 25,234 | $107.53 | $2,713,412.02 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 3 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,563 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $108.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 11,527 | $106.72 | $1,230,161.44 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 2 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,797 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.07 to $107.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 01:04 UTC | Veradermics, Inc MANE · Entity 1907 | Exercise / conversionCommon Stock | 3,452 | $12.19 | $42,079.88 |
DisclosureSEC source: 0001628280-26-057813 · wk-form4_1787101490.xml · nonDerivative · entry 1 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 21:21 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantRestricted Stock Unit (RSU) · Derivative | 16,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-324250 · ownership.xml · derivative · entry 2 Waldman Reid Alexander · CIK 0002107415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2036-07-27 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 21:21 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001193125-26-324250 · ownership.xml · derivative · entry 1 Waldman Reid Alexander · CIK 0002107415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-27 F1 · derivative.exercise_date: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:13 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 47,250 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0002107415-26-000004 · ownership.xml · derivative · entry 1 Waldman Reid Alexander · CIK 0002107415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2036-05-29 F1 · derivative.exercise_date: The option will vest in substantially equal monthly installments over 36 months commencing May 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:00 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005897 · wk-form4_1770336007.xml · derivative · entry 2 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:00 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 1,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005897 · wk-form4_1770336007.xml · nonDerivative · entry 1 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:00 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 556,399 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005897 · wk-form4_1770336007.xml · derivative · entry 3 Waldman Reid Alexander · CIK 0002107415 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,399 Underlying: Common Stock · 556,399 shares Expires 2036-02-03 F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares of Common Stock on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.